The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Targeting Ras in Myeloid Leukemias
Open accessAbstract
Ras proteins normally relay growth-promoting signals from many activated cell surface receptors, and they are altered by oncogenic point mutations in approximately 30% of human cancers. Activating KRAS and NRAS mutations are especially common in malignancies of the pancreas, lung, and colon, and in myeloid leukemia. Here, we discuss general strategies for targeting hyperactive Ras signaling in cancer cells with specific reference to myeloid malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Somatic mutations in Ras have been found recurrently in acute lymphophastic leukemia and myeloid leukemias.1”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Kiel, M. J., Yilmaz, Ö. H., Iwashita, T., Yilmaz, O. H., Terhorst, C., & Morrison, S. J. (2005) · Cell · doi:10.1016/j.cell.2005.05.026 · Cited by 3,168
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data
Sachs, K., Perez, O., Pe'er, D., Lauffenburger, D. A., & Nolan, G. P. (2005) · Science · doi:10.1126/science.1105809 · Cited by 1,708
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Self-citation
Cited by
Autophagy: A lysosomal degradation pathway with a central role in health and disease
Eskelinen, E.-L., & Saftig, P. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.07.014 · Cited by 703
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
Targeting oncogenic Ras signaling in hematologic malignancies
Ward, A. F., Braun, B. S., & Shannon, K. M. (2012) · Blood · doi:10.1182/blood-2012-05-378596 · Cited by 209
Self-citationTherapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches
Konopleva, M., Tabe, Y., Zeng, Z., & Andreeff, M. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.06.001 · Cited by 178
Yokoyama, T., & Nakamura, T. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01914.x · Cited by 163
Metadata
- Authors
- Braun, B. S., & Shannon, K.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Clinical Cancer Research
- Published
- 2008-04-15
- Volume
- 14
- Issue
- 8
- Pages
- 2249-2252
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2129792506
- Cited by
- 74
- References
- 57
- Citations by year
- 2026: 1 · 2025: 3 · 2023: 6 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 6 · 2017: 6 · 2016: 4 · 2015: 3 · 2014: 10 · 2013: 2 · 2012: 4
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society (7019-04)
- National Institutes of Health (W81XWH, CA72614, R37 CA72614)
- National Cancer Institute (U01 CA 84221, R01CA072614, R37 CA72614, U01CA084221, R37CA072614, R01CA104282, K08CA103868)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- Ras signaling, myeloid leukemia, KRAS mutation, NRAS mutation, oncogenic Ras, RAS inhibitors, signal transduction, myeloid neoplasms
- MeSH terms
- Humans, Leukemia, Myeloid, Mutation, Genes, ras, Signal Transduction, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Ras in Myeloid Leukemias. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1005
- The paper
- Braun, B. S., & Shannon, K. (2008). Targeting Ras in Myeloid Leukemias. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.